Skip to main content
NurExone Biologic Inc logo

NurExone Biologic Inc — Investor Relations & Filings

Ticker · NRX ISIN · CA67059R1091 LEI · 25490047UWNZ2P8ESB77 TSXV Manufacturing
Open in API
Filings indexed 423 across all filing types
Latest filing 2025-09-19 Regulatory Filings
Country CA Canada
Listing TSXV NRX

About NurExone Biologic Inc

https://nurexone.com/

NurExone Biologic Inc. is a biopharmaceutical technology company specializing in the development of regenerative exosome-based therapies for Central Nervous System (CNS) injuries. The core of its business is the proprietary ExoTherapy platform, which utilizes nanosized extracellular vesicles (exosomes) as precision biological messengers and drug delivery vehicles. These exosomes are loaded with therapeutic compounds, creating nanodrugs designed to target inflamed or damaged neural tissue. A key product candidate is ExoPTEN, an siRNA sequence loaded onto exosomes, which has shown promise in regenerating and rewiring neurons in preclinical models of fully transected spinal cords. The company employs proprietary 2D and 3D production processes within its dedicated in-house bioreactor to ensure high-quality, large-scale production of potent exosomes.

Recent filings

Filing Released Lang Actions
Report of exempt distribution (45-106F1).pdf
Regulatory Filings Classification · 85% confidence The document is a Canadian securities regulatory form (Form 45-106F1) reporting an exempt distribution of securities, including detailed purchaser, jurisdiction and issuance data. It is not an earnings release, investor presentation, or any of the more specific filings in our taxonomy, but rather a mandatory regulatory disclosure under Canadian rules. It therefore falls under the catch-all Regulatory Filings category (RNS).
2025-09-19 English
News release - English.pdf
Regulatory Filings Classification · 65% confidence The document is a corporate press release announcing operational expansion—the establishment of a U.S. manufacturing facility and receipt of an incentive grant. It does not report on financial results (ER/IR), share issuances or buybacks (SHA/POS), board or management changes (MANG), or fundraising or financing instruments (CAP) in the traditional sense, nor is it an AGM or legal filing. It is a general corporate announcement that does not fit any more specific category, so it falls into the fallback Regulatory Filings category (RNS).
2025-09-16 English
News release - English.pdf
Regulatory Filings
2025-09-11 English
News release - English.pdf
Regulatory Filings Classification · 90% confidence The document is a corporate press release announcing the allowance of a U.S. patent for NurExone’s proprietary exosome manufacturing process. It does not present quarterly or annual financial results (ER, IR, 10-K), nor is it a report itself (IR, 10-K) or announcement of a shareholder meeting (AGM-R, DVA, PSI). It is not related to board changes, insider trades, dividends, share issues, delistings, legal proceedings, M&A, financing, or ESG. It is a general company announcement/press release about intellectual property and supply chain readiness. No specific category fits other than the general “Regulatory Filings” fallback for miscellaneous corporate disclosures. Therefore, it should be classified as RNS.
2025-09-08 English
Material change report - English.pdf
Regulatory Filings
2025-08-29 English
News release - English.pdf
Regulatory Filings
2025-08-28 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.